Last updated: February 28, 2026
What Is NDC 68462-0435?
NDC 68462-0435 refers to a specific drug identified by the National Drug Code (NDC) system managed by the FDA. This code corresponds to Voretigene neparvovec-rzyl (Luxturna), a gene therapy approved for the treatment of inherited retinal disease caused by mutations in the RPE65 gene.
Market Size and Growth Drivers
Current Market Environment
- Market approval: Luxturna received FDA approval in December 2017.
- Indication: Treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy.
- Target population: Estimated at approximately 1,000–2,000 U.S. patients, based on prevalence data.
- Sales Data: Estimated global sales of Luxturna reached around $230 million in 2022 (EvaluatePharma).
Key Growth Factors
- Expanding patient identification: Advances in genetic diagnostics increase the diagnosed patient pool.
- Price and reimbursement: An approximate list price of $425,000 per eye (according to 2022 pricing data) influences market dynamics.
- Regulatory landscape: Accelerated approval pathways and orphan drug designations facilitate market entry.
Competition and Pipeline
- As of 2023, Luxturna is the sole FDA-approved gene therapy for inherited retinal dystrophies.
- Several preclinical and clinical-stage therapies targeting RPE65 and other retinal genes are in development, potentially impacting future market share.
Price Projections
Current Pricing and Revenue Trends
| Year |
Estimated Global Sales |
List Price per Treatment |
Key Factors Influencing Price |
| 2022 |
$230 million |
$425,000 per eye |
Market penetration, reimbursement policies |
| 2025 |
$310–$370 million |
Potential price adjustments |
Increased diagnosis rates, new markets, payer negotiations |
| 2030 |
$450–$600 million |
Possible price adjustments |
Expanded indications, improved access |
Price Drivers
- Price erosion: Limited competitive therapies currently constrain significant price declines.
- Market expansion: Broader adoption in Europe, Japan, and emerging markets could increase revenue.
- Reimbursement negotiations: Payer negotiations could lead to discounts or value-based pricing, balancing volume increases against price reductions.
- Manufacturing costs: Advances in vector production may reduce costs, allowing more flexible pricing strategies.
Regulatory and Market Risks
- Label expansion: Approvals for additional retinal disorders could enlarge the addressable market.
- Pricing pressures: Healthcare policy reforms and pricing transparency efforts risk reducing margins.
- Pipeline competition: Success of alternative gene therapies might pressurize Luxturna's market share.
Strategic Outlook
| Factor |
Implication |
Expected Outcome |
| Market expansion |
Increased patient population |
Sales growth, potentially reaching $600 million globally by 2030 |
| Price adjustments |
Negotiated discounts or tiered pricing |
Mixed impact; volume growth may offset price reductions |
| Technological advances |
Improved vector production or delivery |
Lower costs and increased accessibility |
Key Takeaways
- NDC 68462-0435 (Luxturna) has an established, yet niche, market driven by rare genetic mutations.
- The global sales forecast projects a growth trajectory from approximately $230 million in 2022 towards $600 million by 2030.
- Price trends are subject to regulatory, reimbursement, and pipeline factors, with potential adjustments driven by market expansion and cost efficiencies.
- Competition from emerging therapies could influence pricing and market share.
- Strategic focus on diagnosis expansion and regulatory approvals will be crucial for growth.
FAQs
1. What is the current price of Luxturna?
The list price is approximately $425,000 per eye, with total treatment cost around $850,000 for both eyes.
2. Are there any approved competing therapies?
As of 2023, Luxturna is the only FDA-approved gene therapy for RPE65 mutation-associated retinal dystrophy.
3. What is the size of the eligible patient population in the U.S.?
Estimated between 1,000 and 2,000 patients based on prevalence data.
4. How might future regulatory changes affect prices?
Policy shifts toward value-based pricing and transparency could lead to price negotiations and discounts.
5. What are the main risks to market growth?
Emergence of competing therapies, reimbursement challenges, and limitations in patient diagnosis represent key risks.
References
[1] EvaluatePharma. (2022). Luxturna sales data.
[2] U.S. Food and Drug Administration. (2017). FDA approval for Luxturna.
[3] IQVIA. (2023). U.S. Market for Rare Disease Treatments.
[4] Agency for Healthcare Research and Quality. (2022). Rare disease prevalence data.
